3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Warts
2
Virus Diseases
1
Skin Diseases, Viral
1
Skin Diseases, Infectious
1
Skin Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Papillomavirus Infections
1
Condylomata Acuminata
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
3
Oncolytic Virotherapy
2
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
2
Bevacizumab
2
valrubicin
1
thymoglobulin
1
ledipasvir, sofosbuvir drug combination
1
hepatitis C immune globulin, human
1
halofantrine
1
VP-102
1
Therapies, Investigational
1
Tenofovir
1
Rituximab
1
Radiotherapy, Intensity-Modulated
1
Papillomavirus Vaccines
1
Nimorazole
1
Mitomycin
1
Lamivudine
1
Kidney Transplantation
1
Ipilimumab
1
Interferons
1
Influenza Vaccines
1
Immunoglobulin G
1
Imiquimod
1
Gemcitabine
1
Gels
1
Fluorescent Antibody Technique
1
Drug Therapy
1
Cyclophosphamide
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Virus Diseases
×
VP-102
×
Clear all
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts